Alcohol and hepatocarcinogenesis (original) (raw)
ABSTRACT
- An excessive alcohol intake may result in fatty liver, acute/chronic hepatitis, cirrhosis, and lead to hepatocellular carcinoma (HCC). The aim of this review is to clarify the present condition and the mechanisms of alcohol-related hepatocarcinogenesis and clinical risk factors for alcohol-related HCC. There are several possible mechanisms through which alcohol may induce hepatocarcinogenesis, including the mutagenic effects of acetaldehyde toxicity through the formation of protein and DNA adducts and the production of reactive oxygen species due to the excessive hepatic deposition of iron, changes to lipid peroxidation and metabolism, inflammation and an impaired immune response and modifications to DNA methylation. Furthermore, it has been reported that alcohol accelerates liver carcinogenesis through several signaling pathways including gut-liver axis. From a clinical perspective, it is well known that alcohol interacts with other factors, such as age, gender, viral hepatitis, obesity, and diabetes leading to an increased risk of HCC.
- Keywords: Liver neoplasms; Alcoholics; Carcinogenesis, Liver; Risk factors
INTRODUCTION
Alcohol is classified as a group 1 carcinogen by the International Agency for Research on Cancer because it induces hepatocellular carcinoma like as other cancers in humans.
Worldwide, liver cancer is the second highest cause of cancerrelated death in men and the sixth highest cause of cancer-related death in women. Liver cancer is more common in low-income and middle-income countries than in developed countries [1]. According to the National Cancer Institute, approximately 40,700 cases of liver cancer are expected to be newly diagnosed, and approximately 29,000 patients will die from liver cancer in the USA in 2017. Besides, the incidence of liver cancer is increasing by approximately 3–4% per year [2]. Indeed, liver cancer is a major public health problem. Hepatocellular carcinoma (HCC), which accounts for around 70–90% of cases, is the most common type of primary liver cancer. Alcohol consumption, the level of which is higher in developed countries, especially in the USA and Europe, is one of the frequent causes of HCC in developed countries [3]. The ratio of alcohol abuse to all etiologies of HCC varies according to the country and area; alcohol abuse is reported to be responsible for approximately 15–30% of HCC [4] Understanding the clinical features and the mechanisms of alcohol-based HCC is critically important to the prevention and detection of early-stage HCC and for the development of treatments for HCC. This review summarizes the recent clinical and pathological studies investigating the hepatocarcinogenesis in alcohol-related liver disease (ALD).
THE RISKS OF LIVER CIRRHOSIS AND HCC
According to a World Health Organization report, approximately 280 million individuals, or 4.1% of the population aged >15 years, meet the definition of ‘alcohol-use disorder’ (alcohol dependence and the harmful use of alcohol). The prevalence is almost the same as the prevalence of hepatitis B, and is four times higher than the prevalence of hepatitis C [5]. Because of the large population, HCC screening such as ultrasonography or the measurement of serum tumor marker levels for all of such patients would lead to huge medical costs, thus, it is necessary to select individuals with a high risk of HCC. In this respect, the American Association for the Study of Liver Diseases (AASLD) recommends that patients with Child’s classification A/B cirrhosis undergo surveillance for HCC using ultrasonography with or without alpha-fetoprotein measurement, every 6 months, and does not recommend the modification of the surveillance strategy based on the etiology of liver disease, the strategy of which is almost the same as that recommended by the European Association for the Study of the Liver [5]. Incidentally, the AASLD guidelines for the management of HCC suggested that HCC surveillance is cost-effective if the annual incidence of HCC is 1.5% in patients with cirrhosis [6]. Similar to hepatitis C and hepatitis B, the presence of alcoholic liver cirrhosis is considered to be an important risk factor for the development of HCC. It has been reported that approximately 10–20% of heavy drinkers develop cirrhosis [5]. Several previous studies that have assessed the annual incidence of HCC in patients with alcohol-induced liver cirrhosis have revealed the rate to be 1.9–2.6%, thus, it might be appropriate to perform HCC surveillance for patients with alcoholic liver cirrhosis [7]. However, even when guideline-based surveillance was performed, almost 20–30% of HCC in patients with cirrhosis were diagnosed at a non-early stage [8].
PATHOGENESIS AND GENETICS OF ALCOHOLINDUCED LIVER CARCINOGENESIS
Chronic alcohol intake alters the architecture and compromises the functional capacity of the liver by triggering steatosis, steatohepatitis and cirrhosis [9]. These pathological events are subsequently sustained and participate in the carcinogenetic process. A number of pathophysiological factors are specific to hepatic alcohol-mediated carcinogenesis, including: 1) the formation of acetaldehyde and its direct detrimental effects on proteins and DNA; 2) an elevated production of cytochrome P450 family 2 subfamily E member 1 (CYP2E1)- and/or iron-induced reactive oxygen species (ROS), further aggravated by the impairment of antioxidant defenses and DNA repair mechanisms; 3) changes to the immune system and the induction of chronic inflammation; and 4) interference with methyl group transfer and alterations to gene expression (Fig. 1) [3].
These pathways may be further affected by host-related genetic heterogeneity that could partly explain the difference for inter-individual susceptibility to the development of HCC in patients with alcoholic cirrhosis [3].
HEPATOTOXICITY OF ETHANOL AND TUMOR PROMOTION
Ethanol is oxidized into acetaldehyde by alcohol dehydrogenase (ADH) in the cytosol [10]. Acetaldehyde then enters the mitochondria where it is oxidized to acetate by mitochondrial aldehyde dehydrogenase (ALDH). Acetaldehyde is a highly reactive and directly mutagenic compound which forms various protein and DNA adducts that promote DNA repair failure, lipid peroxidation and mitochondrial damage, and ultimately favor carcinogenesis. Another major pathway of ethanol metabolism includes its oxidation in microsomes by the enzyme CYP2E1, a step that requires nicotinamide adenine dinucleotide phosphate rather than nicotinamide adenine dinucleotide, as for ADH. In parallel, ROS are formed through the metabolism of alcohol by CYP2E1 and the re-oxidation of NADH in the mitochondria [11].
Genetic variations in the alcohol-metabolizing enzymes that modulate the resulting amounts of carcinogenic acetaldehyde have been largely explored as potential inherited markers of alcohol-induced cancers, including those of the liver [12]. In particular, patients with ALD who are homozygous for the ADH1C*1 allele (thought to confer higher enzymatic activity) appear to be more vulnerable to the onset of HCC [13]. Similarly, the weakly active ALDH2*2-conferring allele has been found to be associated with liver cancer in excessive drinkers [14].
ALCOHOL-INDUCED OXIDATIVE STRESS AND IRON METABOLISM
A pivotal mechanism implicated in alcohol-related hepatocarcinogenesis is oxidative stress, which is secondary to ROS derived from alcohol metabolism, inflammation and increased iron storage. Indeed, ROS promote damage to cellular macromolecules and participate in the progression of liver carcinogenesis through the formation of lipid peroxides such as 4-hydroxy-nonenal [15]. An accumulation of ROS causes structural and functional alterations to DNA and affects gene functions such as replication and transcription, and plays a major role in cancer initiation and promotion [16]. ROS accumulation also induces the production of various cytokines, the activation of immune cells and the upregulation of angiogenesis and the metastatic process [17].
ROS include hydroxyethyl, superoxide anion, hydroxyl radicals and numerous free radicals that accumulate following the successive actions of pro- and antioxidant enzymes, while antioxidant defenses are impaired by ethanol consumption, genetic variants affecting the enzymes that regulate the production and detoxification of ROS have been shown to modulate the outcome of ALD. In particular, myeloperoxidase (MPO), which catalyzes the reaction between H2O2 and Cl- to form the highly reactive hypochlorous acid (HOCl) and anion, 37 is affected by a G to A base exchange at position -463 involving its promoter [18]. Additionally, manganese superoxide dismutase (SOD) 2 generates H2O2 within the mitochondria, leading to the formation of highly reactive HOCl [18]. A genetic dimorphism substitutes either alanine (Ala) or valine in the mitochondrial targeting sequence of SOD2 and results in higher mitochondrial activity for the Ala-SOD2 variant. In large prospective cohorts of patients with alcoholic cirrhosis, it was shown that the carriage of 2 G-MPO alleles and/or the possession of at least one Ala-SOD2 allele alone were independent risk factors for the onset of HCC [12]. These variants were also associated with liver iron overload, possibly through enhanced mitochondrial hydrogen peroxide production, a condition which has also been reported to be associated with a risk of HCC in these patients, along with the usual HFE gene mutations [19].
ACTIVATION OF INNATE IMMUNITY, CYTOKINE AND CHEMOKINE SYSTEMS
Alcohol interacts with the immune system and affects tumor immune surveillance, both mechanisms which may relate with tumor development and progression. The innate immune response aims to identify cancerous clones in order to inactivate transforming cells. This response is promoted by inflammatory mediators (chemokines and cytokines) which are produced by various immune cells [18]. Alcohol consumption increases gut permeability and the translocation of bacteria-derived lipopolysaccharide (LPS) from the gut to the liver, in Kupffer cells, LPS interacts with toll-like receptor (TLR) 4, which leads to the production of pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α [18]. These molecules are major pathways involved in hepatocarcinogenesis [20]. Although the precise mechanisms by which pro-inflammatory cytokines promote liver cancer development are not fully understood, their signals regulate gene expression through the signal transducer and activator of transcription 3(STAT3) and nuclear factor-κB (NF-κB) transcription factors. NF-κB, one of the main transcriptional regulators of the inflammatory response, is activated during ALD and increases the production of various pro-inflammatory mediators which include TNF-α, IL-1, IL-6, EGF and TLRs, the latter promote ROS accumulation and activate STAT3, thus participating in cancer development [21]. In patients with ALD, the highly productive cytokine IL-6 -174G allele is associated with HCC, and epidermal growth factor (EGF) promotes cancer growth and invasiveness, and which is subject to functional polymorphism involving an A to G exchange in the 50 untranslated region of the EGF gene [18]. The G allele, resulting in higher transcription levels, has been associated with the presence of HCC in Caucasian populations affected by alcohol- or hepatitis C virus (HCV)-related liver diseases, a finding that was further confirmed by a recent meta-analysis [22].
MODULATION OF LIPID METABOLISM
Alcohol abuse is characterized by an accumulation of fat (mainly triglycerides, phospholipids and cholesterol esters) in hepatocytes. Initially revealed by genome-wide association studies, some single nucleotide polymorphisms (SNPs) might associated with hepatocarcinogenesis (Table 1). A SNP (rs738409 C>G for I148M) in the adiponutrin/patatin-like phospholipase domain containing protein 3 (PNPLA3) protein sequence has rapidly become a well-established genetic factor associated with steatosis and fibrosis in patients with ALD [12]. This genetic variation is considered a loss-of-function mutation that promotes intracellular triglyceride accumulation and lipotoxicity in hepatocytes [18]. The rs738409 (G) allele has been highlighted as a major genetic driver of liver cancer development in patients with alcoholic cirrhosis by numerous European research groups in the context of both large case- control and prospective studies, as well as subsequent meta-analyses [18]. Other polymorphisms affecting genes involved in lipid metabolism have also been proposed [18].
GUT-LIVER AXIS AND HEPATOCARCINOGENESIS
Consolidating evidence arose in recent years indicating that alcohol not only alters the quantitative and qualitative composition of the microbiome, but also induces alterations of the epithelial intestinal barrier with consequent release of bacteria and bacterial products that fuel the inflammatory response in the liver. It has been demonstrated that, upon alcohol exposure, LPS and other bacterial products are released into the circulation and can bind to members of the TLRs family on the cellular membrane of hepatic resident macrophages (Kupffer cells), thereby triggering the production of pro-inflammatory mediators in these cells [23]. Fecal microbiota transplantation and fecal microbiota manipulation via use of prebiotics might represent a valuable therapy against alcoholic liver injury and steatosis [24,25]. Recent pioneering work has identified gut-liver communication and the microbiome as important components involved in the development of ALD [26,27]. The unpublished data from our institute, in alcohol-related cirrhotic patients, status of dysbiosis was associated and with hepatocarcinogenesis and an independent risk factor for developing HCC.
CLINICAL RISK FACTORS
Age is one of the most significant risk factors for many malignancies including HCC in ALD patients [18]. Alcohol consumption has been associated with an increased risk of several malignancies, this risk starting at doses as low as 10 g/1 unit/day [28]. It is an independent risk factor for the development of HCC, with a relative risk of 2.07 for heavy drinkers compared to non-drinkers and the relative risk is also slightly increased in occasional drinkers, while in the setting of non-fibrotic liver F0/F1, heavy alcohol consumption is no longer associated with an HCC risk after adjustment for smoking habits and metabolic syndrome [29].
There might be a gender difference in the volume of alcohol intake that increases the risk of alcohol-induced liver damage and the development of HCC. It has been reported that the risk of developing cirrhosis becomes substantial with the consumption of 60–80 g/day of alcohol for 10 years in men and 20 g/day for 10 years in women [14,23]. In addition, women showed a more rapid progression (20 years) to cirrhosis than men (35 years) [30]. Among individuals who consume more than 80 g/day of alcohol, the risk of HCC development in women has been shown to be almost fivefold higher than that in men [30]. However, the overall prevalence of HCC in women is small compared with that in men. Various mechanisms have been suggested to underlie the higher sensitivity of women to alcohol. After the oral administration of alcohol, women show less first-pass metabolism of alcohol, which is defined as the difference in the amount of orally administered ethanol and the quantities in the systemic blood, due to their lower gastric ADH activity, which results in a higher serum concentration of alcohol [31]. Thus, even when the same amount of ethanol is consumed, the female liver may be exposed to more ethanol. Furthermore, estrogen, a female sex hormone, may play an important role in alcohol-induced liver injury. It has been shown that estrogen increases the sensitivity of Kupffer cells to LPS, which results in more severe liver injury, and many previous studies have reported that more severe inflammatory responses in the liver and fat tissue, which were associated with TLR4 signaling, were seen in female patients [5].
In patients with ALD, the coexistence of hepatitis virus has been shown to accelerate the disease course. In patients with a high alcohol intake (>60 g/day to 125 g/day), the coexistence of HCV has been shown to increase the risk of alcohol-associated liver cirrhosis [5]. Furthermore, heavy alcohol consumption has also been shown to increase the risk of developing HCC [5]. Patients with coexisting hepatitis B virus (HBV) are at increased risk of developing fibrosis and HCC [5]. In addition, self-resolved HBV infection can be a risk factor for developing HCC in patients with alcoholic cirrhosis [5].
Moreover, alcohol synergizes with other risk factors for HCC, such as diabetes mellitus and viral hepatitis. In patients consuming excessive alcohol, defined as over 80 g/day, the risks of HCC rose from 2.4 to 9.9 in patients with diabetes, and from 19.1 to 53.9 in patients with HCV infection [32,33]. Obesity also has a synergistic effect [34].
Conversely, alcohol cessation is associated with a risk of HCC that falls by 6–7% per year, but the detrimental effects of alcohol can remain for decades, a wash-out period of 23 years being necessary to achieve the same incidence of HCC seen in abstinent patients. However, these results need to be considered with caution as this analysis only included four studies [35].
CONCLUSION
Several clinical factors increase the risk of alcohol-induced HCC. A large alcohol intake, coexistence of diabetes and hepatitis virus infection, and female gender are established factors. For the mechanisms of hepatocarcinogenesis are increasing evidence to suggest that many factors are involved. Alcohol metabolites and adducts have been shown to induce oxidative stress, direct mutagenesis, the aberrant methylation of DNA or protein on hepatocytes, and the immune system might be implicated in the development and progression of HCC. Further studies are needed to reduce the risk of HCC.
FOOTNOTES
Conflicts of Interest
The author has no conflicts to disclose.
Figure 1.
A number of pathophysiological factors are related with ethanol induced hepatocarcinogenesis including the formation of acetaldehyde and DNA adducts which effects on proteins and DNA, an elevated production of cytochrome P450 2E1, and ROS. ADH, alcohol dehydrogenase; CYP2E1, cytochrome P450 family 2 subfamily E member 1; ROS, reactive oxygen species; ALDH, aldehyde dehydrogenase.
Table 1.
Summary of the most SNPs with hepatocarcinogenesis in ALD
Table 1.
| Gene name | Main identified SNPs | Protein functionality |
|---|---|---|
| Alcohol dehydrogenase (ADH) | ADH1B*2, ADH1B*3, ADH1C*1 | Increased enzymatic activity |
| Aldehyde dehydrogenase (ALDH) | ALDH2*2 | Reduced enzymatic activity |
| Cytochrome P450 family 2 subfamily E member 1 (CYP2E1) | Pastl/Rsal | Increased enzymatic activity |
| Methylenetetrahydrofolate reductase (MTHFR) | C677T | Reduced enzymatic activity |
| Patatin-like phospholipase domain containing protein 3 (PNPLA3) | I148M | Loss of enzymatic function |
| Transmembrane 6 superfamily member 2 (TM6SF2) | E167K | Loss of expression and function |
| Neurocan (NCAN) | rs2228603 T allele | Altered functionality, unclear mechanisms |
Abbreviations
AASLD
the American Association for the Study of Liver Diseases
ALD
alcohol-related liver disease
CYP2E1
cytochrome P450 family 2 subfamily E member 1
PNPLA3
patatin-like phospholipase domain containing protein 3
SNP
single nucleotide polymorphism
STAT3
signal transducer and activator of transcription 3
REFERENCES
- 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
- 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
- 3. Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol 2014;20:15943-15954.
- 4. Hlady RA, Tiedemann RL, Puszyk W, Zendejas I, Roberts LR, Choi JH, et al. Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget 2014;5:9425-9443.
- 5. Matsushita H, Takaki A. Alcohol and hepatocellular carcinoma. BMJ Open Gastroenterol 2019;6:e000260.
- 6. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67:401-421.
- 7. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007;46:1104-1110.
- 8. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-1997.
- 9. Salaspuro M. Acetaldehyde: a cumulative carcinogen in humans. Addiction 2009;104:551-553.
- 10. Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res Health 2007;30:38-47.
- 11. Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand J Gastroenterol 2009;44:912-925.
- 12. Nahon P, Sutton A, Rufat P, Ziol M, Akouche H, Laguillier C, et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 2009;50:1484-1493.
- 13. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004;24:217-232.
- 14. Brandon-Warner E, Walling TL, Schrum LW, McKillop IH. Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis. Alcohol Clin Exp Res 2012;36:641-653.
- 15. Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, Goswami PC. Redox control of the cell cycle in health and disease. Antioxid Redox Signal 2009;11:2985-3011.
- 16. Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 2015;16:2129-2144.
- 17. Hagymási K, Blázovics A, Lengyel G, Kocsis I, Fehér J. Oxidative damage in alcoholic liver disease. Eur J Gastroenterol Hepatol 2001;13:49-53.
- 18. Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-293.
- 19. Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res 2010;29:18.
- 20. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
- 21. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012;143:550-563.
- 22. Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, et al. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012;7:e32159.
- 23. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009;50:1258-1266.
- 24. Ferrere G, Wrzosek L, Cailleux F, Turpin W, Puchois V, Spatz M, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol 2017;66:806-815.
- 25. Shasthry SM. Fecal microbiota transplantation in alcohol related liver diseases. Clin Mol Hepatol 2020;26:294-301.
- 26. Ramadori P, Cubero FJ, Liedtke C, Trautwein C, Nevzorova YA. Alcohol and hepatocellular carcinoma: adding fuel to the flame. Cancers (Basel) 2017;9:130.
- 27. Cassard AM, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol 2018;24:100-107.
- 28. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:1314-1321.
- 29. Crawford JM. Histologic findings in alcoholic liver disease. Clin Liver Dis 2012;16:699-716.
- 30. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-331.
- 31. Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001;25:502-507.
- 32. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213.
- 33. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938-1946.
- 34. Grewal P, Viswanathen VA. Liver cancer and alcohol. Clin Liver Dis 2012;16:839-850.
- 35. Heckley GA, Jarl J, Asamoah BO, G-Gerdtham U. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011;11:446.
Citations
Citations to this article as recorded by
- Leveraging cancer metabolism to translate into effective therapeutics
Jie Xu, Linlin Guo, Yi Wang, Xiaoping Li, Ping Yi, Chunming Cheng
Seminars in Cancer Biology.2026; 118: 44. CrossRef - Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study
Yewon Choi, Sungmin Cho, Changdai Gu, Chungho Kim, Bomi Park, Hwiyoung Kim
BMC Medical Informatics and Decision Making.2026;[Epub] CrossRef - A Multi-Stimuli-Responsive Steroid-Based Nanosystem for Apigenin Delivery and Time-Dependent Anti-HCC Activity In Vitro
Luwen Luo, Yaoxiao Liang, Luchang Chen, Weipeng Yang, Shenglin You, Chunying Luo, Cheng Lin
Journal of Inorganic and Organometallic Polymers and Materials.2026;[Epub] CrossRef - NADH-Activated Near-Infrared Fluorescent Probe for Efficient Screening of ADH/ALDH2 Dual Agonists for Alcohol Detoxification
Jiwei Li, Xunfang Ding, Qilin Zhou, Lei Sun, Jin Yan, Qian Li, Hao Liu, Renshi Li, Fanchao Feng, Bo Chen, Jiangwei Tian
Analytical Chemistry.2026;[Epub] CrossRef - Global, regional, and national burden of liver cancer due to alcohol use, 1990–2021: results from the Global Burden of Disease study 2021
Qihong Wang, Wen Jia, Jiao Liu, Qian Zhao, Zhuo Yang
European Journal of Gastroenterology & Hepatology.2025; 37(4): 466. CrossRef - Construction and validation of a diagnostic model for cholangiocarcinoma based on tumor-educated platelet RNA expression profiles
Haiyang Hu, Jiefeng He, Haoliang Zhao
Oncologie.2025; 27(2): 277. CrossRef - Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura
Medical Oncology.2025;[Epub] CrossRef - Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: The tip of the iceberg?
Zhi-Quan Xu, Shi-Qiao Luo, Zhong-Jun Wu, Rui Liao
BioScience Trends.2025; 19(3): 266. CrossRef - The epidemiology, etiology, and future prophylactic options for cancers in Mainland China
Hongsen Chen, Jie Xu, Wenbin Liu, Xi Chen, Ping Li, Guangwen Cao
Frontiers in Oncology.2025;[Epub] CrossRef - Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
Zhiqing Zhang, Hong Yang, Fei Han, Peng Guo
Current Issues in Molecular Biology.2025; 47(6): 464. CrossRef - Hepatocellular carcinoma in patients without cirrhosis
Karina Sato-Espinoza, Mayra Valdivia-Herrera, Perapa Chotiprasidhi, Javier Diaz-Ferrer
World Journal of Gastroenterology.2025;[Epub] CrossRef - Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice
Song-xia Zhang, Fang-fang Hu, Huan Chen, Jing Guo, Zhong-wen Xiang, Xin Ding, Meng-ling Ye, Wen-li Ye, Jun-hong Chen, Xin Wang, Wen-jing Han, Hong-hao Zhou, Wei Zhang, Yun Huang, Lie-lin Wu, Guang-hui Lian, Yao Chen
npj Biofilms and Microbiomes.2025;[Epub] CrossRef - Cis-Regulatory Alterations in FOXP4 Modulate Esophageal Cancer Susceptibility Induced by Chronic Alcohol Exposure
Siyuan Niu, Jialing Ma, Shasha Liu, Yueping Li, Xinying Yue, Miaoxin Pan, Lina Song, Yutong Wu, Zifei Yang, Yuqian Tan, Linglong Gu, Chaolong Wang, Jiang Chang
Cancer Research.2025; 85(14): 2591. CrossRef - Identification of a novel ferroptosis-related gene signature in hepatocellular carcinoma: clinical significance, tumor microenvironment, drug sensitivity, and gene landscape analysis
Yunzhao Hu, Chenchen Hao, Chengyuan Dong, Ping Tao, Jia Wang, Qun Lu
Discover Oncology.2025;[Epub] CrossRef - Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines
Masaaki Mino, Eiji Kakazu, Tatsuya Kanto
Gut and Liver.2025; 19(5): 651. CrossRef - Construction of a hepatocellular carcinoma high-risk population rating scale and independent predictors' assessment
Manyu Li, Jing Sun, Yan Wang, Jun Ma, Xiaotian Hao, Yan Liu, Cheng Zhou, Haiwei Zhou
The American Journal of the Medical Sciences.2024; 367(3): 181. CrossRef - Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
Karli R. LeFort, Wiramon Rungratanawanich, Byoung-Joon Song
Cellular and Molecular Life Sciences.2024;[Epub] CrossRef - Inequities in primary liver cancer in Europe: The state of play
Loreta A. Kondili, Jeffrey V. Lazarus, Peter Jepsen, Frank Murray, Jörn M. Schattenberg, Marko Korenjak, Lucia Craxì, Maria Buti
Journal of Hepatology.2024; 80(4): 645. CrossRef - Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut–Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications
Tianhui Gao, Shuyi Wang, Zongping Zhu, Liting Lin, Yirong Luo, Meigui Lu, Wan Liao
The American Journal of Chinese Medicine.2024; 52(02): 387. CrossRef - Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
European Journal of Gastroenterology & Hepatology.2024; 36(4): 430. CrossRef - A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
Yu-Jie Jiang, Ye-Ming Cao, Yong-Bing Cao, Tian-Hua Yan, Cheng-Lin Jia, Ping He
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1511. CrossRef - A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population
Yuanlin Zou, Jicun Zhu, Caijuan Song, Tiandong Li, Keyan Wang, Jianxiang Shi, Hua Ye, Peng Wang
Cancer Medicine.2024;[Epub] CrossRef - CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
Feifan Yao, Suiqing Zhou, Ruizhi Zhang, Yining Chen, Wei Huang, Kai Yu, Nanmu Yang, Xiangjun Qian, Xiaofeng Tie, Jiali Xu, Yu Zhang, Tasiken Baheti, Jing Xu, Xinzheng Dai, Xiaopei Hao, Liren Zhang, Xuehao Wang, Qing Li
Cancer Letters.2024; 593: 216935. CrossRef - Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Liver Cancer.2024; 13(5): 561. CrossRef - Causal associations between platelet count, alcohol consumption, and the risk of liver hepatocellular carcinoma based on a Mendelian randomization study
Lihua Yu, Leisheng Wang, Yuzheng Xue, Yilin Ren, Tianhao Liu, Hao Hu
Frontiers in Endocrinology.2024;[Epub] CrossRef - Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment
Fei Feng, Yue Zhao
Medical Principles and Practice.2024; 33(5): 414. CrossRef - Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
International Journal of Molecular Sciences.2024; 25(13): 7191. CrossRef - Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
Cancer Medicine.2024;[Epub] CrossRef - Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C)
Paul J. Clark, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Nicoll, Amanda Wade, Wendy
Drug and Alcohol Review.2024; 43(6): 1559. CrossRef - Role of Epigenetic Factors in Determining the Biological Behavior and Prognosis of Hepatocellular Carcinoma
Sami Akbulut, Zeynep Kucukakcali, Tevfik Tolga Sahin, Cemil Colak, Sezai Yilmaz
Diagnostics.2024; 14(17): 1925. CrossRef - Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma—From Inflammation to Hepatocellular Carcinoma Progression
Jacek Baj, Magdalena Kołodziej, Joanna Kobak, Jacek Januszewski, Kinga Syty, Piero Portincasa, Alicja Forma
International Journal of Molecular Sciences.2024; 25(19): 10233. CrossRef - Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy
Israa M. Helal, Monica A. Kamal, Mostafa K. Abd El-Aziz, Hend M. El Tayebi
Expert Reviews in Molecular Medicine.2024;[Epub] CrossRef - Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Seren M. Gedallovich, Paul Y. Kwo
Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef - Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application
Lin Su, Jiawen Bu, Jiahui Yu, Mila Jin, Guanliang Meng, Xudong Zhu
Clinical and Translational Medicine.2024;[Epub] CrossRef - Application of nanotechnology in the treatment of hepatocellular carcinoma
Liu Cai, Yanyuan Du, Hongtai Xiong, Honggang Zheng
Frontiers in Pharmacology.2024;[Epub] CrossRef - ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation
Li Song, Shuo Huang, Honghao Yan, Qing Ma, Qihan Luo, Jiang Qiu, Minxia Chen, Zongyuan Li, He Jiang, Yufan Chen, Fangming Chen, Yu Du, Haozhe Fu, Lisha Zhao, Kanglu Zhao, Ping Qiu
Frontiers in Pharmacology.2024;[Epub] CrossRef - A nonlinear relationship between alcohol consumption and cognitive function in elderly people: a population-based study from NHANES 2011–2014
Kaiqi Chen, Yunhua Li, Rui Yue, Zhao Jin, Shikui Cui, Xijian Zhang, Danping Zhu, Qihui Li
Frontiers in Aging Neuroscience.2024;[Epub] CrossRef - Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma
Sha Li, Pei Xue, Xun Diao, Qi-Yu Fan, Kun Ye, Xiao-Mei Tang, Jia Liu, Zhong-Yan Huang, Qing-Hai Tang, Cheng-You Jia, Rui Xin, Zhong-Wei Lv, Ji-Bin Liu, Yu-Shui Ma, Da Fu
Journal of Advanced Research.2023; 54: 133. CrossRef - The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Sae Hamaya, Koji Fujita, Tsutomu Masaki
International Journal of Molecular Sciences.2023; 24(3): 2805. CrossRef - Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy
Chern-Horng Lee, Chien-Heng Shen, Cho-Li Yen, Tzung-Hai Yen, Sen-Yung Hsieh
Journal of Personalized Medicine.2023; 13(3): 397. CrossRef - The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef - Ring finger protein 12 activates AKT signalling to promote the progression of liver cancer by interacting with EGFR
Chengpeng Yu, Dean Rao, Tiantian Wang, Jiaqi Sheng, Enjun Lv, Long Zhang, Xun Lu, Jingjing Yu, Huifang Liang, Jia Song, Wenjie Huang
Journal of Cellular and Molecular Medicine.2023; 27(11): 1523. CrossRef - The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study
Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
PLOS Medicine.2023; 20(6): e1004244. CrossRef - Increased age, bilirubin, international normalized ratio, and creatinine score to triglyceride ratio are associated with alcohol-associated primary liver carcinoma: a single-centered retrospective study
Xiaoqing Jia, Rong Li, Xiaoting Zhang, Tao Zhou, Dalong Sun, Na Yang, Zheng Luo
Lipids in Health and Disease.2023;[Epub] CrossRef - Association between pro-inflammatory diet and liver cancer risk: a systematic review and meta-analysis
Kaixia Chen, Fen Yang, Xinhong Zhu, Guiyuan Qiao, Chunmei Zhang, Junxiu Tao, Xiaolian Gao, Mingzhong Xiao
Public Health Nutrition.2023; 26(12): 2780. CrossRef - Alcohol: Immunomodulatory Effects and Cancer
Juan C. Molina, Jesús D. Guerrero-Morán, Claudia González-Espinosa
Revista de Investigación Clínica.2023; 75(3): 129. CrossRef - Epigenetics in hepatocellular carcinoma
Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Bassel F. El-Rayes
Seminars in Cancer Biology.2022; 86: 622. CrossRef - Alcohol triggered bile acid disequilibrium by suppressing BSEP to sustain hepatocellular carcinoma progression
Wenbo Chen, Qisong Zhang, Ming Ding, Jingjing Yao, Yajuan Guo, Wenxin Yan, Shaofang Yu, Qinghong Shen, Min Huang, Yaqiu Zheng, Yuefang Lin, Ying Wang, Zhongqiu Liu, Linlin Lu
Chemico-Biological Interactions.2022; 356: 109847. CrossRef - GARS is implicated in poor survival and immune infiltration of hepatocellular carcinoma
Jinghui Wang, Bing Yang, Dingxue Wang, Rui Han, Zhanyang Bi, Lizhu Lin
Cellular Signalling.2022; 94: 110302. CrossRef - The pathogenesis of liver cancer and the therapeutic potential of bioactive substances
Song Gao, Xingyue Jiang, Liang Wang, Shanshan Jiang, Hanyuan Luo, Yan Chen, Cheng Peng
Frontiers in Pharmacology.2022;[Epub] CrossRef - The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
Bo Sun, Lijie Zhang, Dongqiao Xiang, Qing Li, Yanqiao Ren, Yanyan Cao, Tao Sun, Weihua Zhang, Linxia Wu, Licheng Zhu, Lei Chen, Huangxuan Zhao, Chuansheng Zheng, Alessandro Granito
Journal of Oncology.2022; 2022: 1. CrossRef - Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance
Bao Q. Lam, Rashmi Srivastava, Jason Morvant, Sharmila Shankar, Rakesh K. Srivastava
Cells.2021; 10(11): 3077. CrossRef - The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma
Ye Xu, Qinglong Guo, Libin Wei
Cancers.2021; 13(20): 5096. CrossRef